Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response

Abstract The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5 months after discontin...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2012-06, Vol.36 (6), p.689-693
Main Authors: Yhim, Ho-Young, Lee, Na-Ri, Song, Eun-Kee, Yim, Chang-Yeol, Jeon, So Yeon, Shin, Seunghwan, Kim, Jeong-A, Kim, Hee Sun, Cho, Eun Hae, Kwak, Jae-Yong
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Benzamides
Chronic myeloid leukemia
Complete molecular response
Feasibility Studies
Female
Follow-Up Studies
Fusion Proteins, bcr-abl - analysis
Fusion Proteins, bcr-abl - genetics
Hematology, Oncology and Palliative Medicine
Humans
Imatinib
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics
Male
Middle Aged
Molecular Diagnostic Techniques
Neoadjuvant Therapy
Piperazines - administration & dosage
Piperazines - therapeutic use
Pyrimidines - administration & dosage
Pyrimidines - therapeutic use
Real-time quantitative polymerase chain reaction
Remission Induction
Retrospective Studies
Risk factors
Withholding Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5 months after discontinuation of IM. All 7 patients with high Sokal risk were relapsed. The probability of CMR persistence at 1-year was 28.6%. All relapsed patients were still responsive to IM. A high Sokal risk and delayed acquisition of CMR were associated with relapse. IM discontinuation in patients achieved CMR after treatment with front-line IM might be feasible. Further studies are warranted.
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2012.02.011